News | August 28, 2012

ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents

August 28, 2012 — The International Contrast Ultrasound Society (ICUS) applauded the U.S. Food and Drug Administration’s (FDA) decision to modify the U.S. product label for Optison, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans. Optison is marketed by GE Healthcare.

The label change was supported by a citizen petition filed by ICUS in October, citing newer scientific studies showing the superior safety profile of ultrasound contrast agents along with their favorable risk-benefit ratios. The citizen petition, which was granted in part by the FDA, also supported a prior modification of the label for Definity, an ultrasound contrast agent marketed by Lantheus Medical Imaging.

The FDA's actions are "an important step forward for patients and for our healthcare system," said Steven Feinstein, a cardiologist at Rush University Medical Center in Chicago and ICUS co-president.

Ultrasound contrast agents are administered intravenously during a noninvasive ultrasound scan to improve image clarity. The procedure does not expose patients to ionizing radiation, and ultrasound contrast agents do not contain dye or increase a patient's risk of nephrotoxicity, according to Feinstein.

"Ultrasound contrast agents are exceedingly safe and completely radiation-free diagnostic imaging tools," he said. "By improving the reliability of a simple front-line ultrasound scan, ultrasound contrast agents also may reduce the need for redundant, expensive and potentially riskier downstream testing — thereby improving patient care while also reducing the overall cost of diagnostic imaging."

The FDA's decision also will spare many patients from the cumulative effects of ionizing radiation that are inherent in certain alternative forms of diagnostic imaging, including SPECT (single photon emission computed tomography) and CT (computed tomography), according to Michael Main, cardiologist and director of the echocardiography laboratory at St. Luke’s Mid-America Heart Institute in Kansas City, Mo., and ICUS treasurer. "The FDA decision should lead to increased use of contrast, better imaging studies, better diagnosis for patients and saved lives," he said.

Main said that although the FDA retained boxed warnings on both ultrasound contrast agents, newer safety data demonstrate a more favorable risk-benefit profile that ultimately may warrant additional label changes with removal of the boxed warnings.

For more information: www.icus-society.org

Related Content

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

News | Cardiovascular Ultrasound | November 14, 2019
November 14, 2019 — Ultromics has received 510(k) clearance from the U.S.

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
Mindray announced its partnership with Cincinnati Children's Hospital Medical Center, one of the top children's hospitals in the United States
News | Ultrasound Imaging | November 13, 2019
November 13, 2019 – Mindray announced its partnership with...
Using artificial intelligence to predice risk of thyroid cancer on ultrasound.

Using artificial intelligence to predice risk of thyroid cancer on ultrasound.

News | Artificial Intelligence | November 06, 2019
November 6, 2019 — Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the gen
Windsong Radiology Group

Windsong Radiology Group

Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019
Windsong Radiology Group is a New York-based radiolo
The Konica Minolta Sonimage HS1 hand-carried system is designed for point of care ultrasound (POCUS) use for an immediate, quick look inside the patient. POCUS systems from several vendors are seeing rapid growth.

The Konica Minolta Sonimage HS1 hand-carried system is designed for point of care ultrasound (POCUS) use for an immediate, quick look inside the patient. POCUS systems from several vendors are seeing rapid growth.

Feature | Ultrasound Imaging | October 24, 2019 | Joan Toth
With the miniaturization of technology, improved ease of use, lower system cost, increased portability, and greater
Exact Imaging Receives FDA 510(k) Clearance for Sterile Transperineal Needle Guide
Technology | Ultrasound Imaging | October 24, 2019
Exact Imaging received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sterile Transperineal Needle...
The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Philips Partners With PURE on Tele-Ultrasound Program for Physicians in Rwanda
News | Ultrasound Imaging | October 09, 2019
Philips and non-profit organization PURE (Point-of-care Ultrasound in Resource-limited Environments) highlighted a tele...